Cenk Sumen, PhD, is Chief Technology Officer of Stemson Therapeutics and member of the Board of Directors. He is a globally recognized expert in gene and cell therapy manufacturing and automation, and he brings over a decade of experience in the biotech and biopharmaceutical industries. He has worked closely with many of the pioneering cell therapy developers to support strategic consulting and clinical manufacturing while serving as a technical and business development leader at PCT, helping position this key boutique CDMO for acquisition by Hitachi Chemical. Prior to joining Stemson, Cenk served as the Director of Business Development for the BioProduction Division at ThermoFisher Scientific, where he was responsible for identifying and developing novel biopharmaceutical manufacturing technologies, setting up several key innovation partnerships. He currently serves in the Outreach & Communication (former Chair) and Publication Committees for the American Society of Gene & Cell Therapy. Cenk earned his BS in Biology at MIT and his PhD in Microbiology & Immunology at Stanford University, completing post-doctoral studies in cancer immunology at Harvard Medical School and Memorial Sloan-Kettering Cancer Center.